Abstract: In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VP1.
Type:
Application
Filed:
March 15, 2013
Publication date:
February 19, 2015
Applicant:
Biogen Idec MA Inc.
Inventors:
Kenneth Simon, Thomas Cameron, Deping Wang, Joseph Arndt, Mia Rushe, Justin Caravella, Eric Day
Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
Type:
Application
Filed:
October 27, 2014
Publication date:
February 12, 2015
Applicant:
BIOGEN IDEC MA INC.
Inventors:
David J. BURKE, Shaun E. BUCKLEY, Sherwood Russ LEHRMAN, Barbara Horsey O'CONNOR, James CALLAWAY, Christopher P. PHILLIPS
Abstract: Biomarkers useful for identifying treatments for and monitoring treatment of patients with multiple sclerosis (MS) are provided, as well as methods for their identification, methods of diagnosing MS, relapse of MS patients and disease progression in MS patients.
Type:
Application
Filed:
February 27, 2014
Publication date:
January 29, 2015
Applicant:
BIOGEN IDEC MA INC.
Inventors:
Aaron B. Kantor, Susan E. Goelz, Jun Deng, Hua Lin, Christopher Becker
Abstract: The present invention provides a VWF fragment comprising the D? domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
Type:
Application
Filed:
January 12, 2013
Publication date:
January 22, 2015
Applicant:
BIOGEN IDEC MA INC.
Inventors:
Ekta Seth Chhabra, Tongyao Liu, Robert T. Peters, Haiyan Jiang
Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.
Abstract: The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune responses with such aglycosylated anti-CD154 antibodies or antibody derivatives thereof.
Type:
Application
Filed:
May 16, 2014
Publication date:
January 15, 2015
Applicant:
BIOGEN IDEC MA INC.
Inventors:
Frederick R. Taylor, Christopher D. Benjamin, Linda C. Burkly, Ellen A. Garber
Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.
Type:
Grant
Filed:
July 17, 2013
Date of Patent:
January 13, 2015
Assignee:
Biogen Idec MA Inc.
Inventors:
Mary D. DiBiase, Wen-Li Chung, Mark Staples, Eric Scharin
Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
January 13, 2015
Assignee:
Biogen Idec MA Inc.
Inventors:
Sha Mi, John McCoy, R. Blake Pepinsky, Daniel H. S. Lee
Abstract: In one aspect, the disclosure provides methods for using NMR and NIR to evaluate biological samples. In some embodiments, the methods include a step of performing a Nuclear Magnetic Resonance (NMR) analysis on a sample to obtain an NMR spectrum, a step of performing a Near Infrared Spectroscopy (NIR) analysis on the sample to obtain an NIR spectrum, and/or a step of performing a data fusion analysis to evaluate the NIR spectrum.
Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
Type:
Grant
Filed:
September 6, 2012
Date of Patent:
December 2, 2014
Assignee:
Biogen Idec Ma Inc.
Inventors:
David J. Burke, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway, Christopher P. Phillips
Abstract: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.
Abstract: The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.
Type:
Grant
Filed:
July 5, 2013
Date of Patent:
November 25, 2014
Assignee:
Biogen Idec MA Inc.
Inventors:
Sha Mi, Kenneth J. Rhodes, R. Blake Pepinsky
Abstract: The present invention features inter alia polypeptides comprising heterodimeric Fc regions. In addition, the instant invention provides methods for treating or preventing a disease or disorder in subject by administering the polypeptides of the invention to said subject.
Type:
Application
Filed:
July 13, 2012
Publication date:
November 20, 2014
Applicant:
BIOGEN IDEC MA INC.
Inventors:
Frederick R. Taylor, Justin A. Caravella, Alexey A. Lugovskoy, Amna Saeed-Kothe, Ellen A. Garber
Abstract: The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.
Type:
Grant
Filed:
August 17, 2007
Date of Patent:
November 18, 2014
Assignee:
Biogen Idec MA Inc.
Inventors:
Scott Glaser, Stephen Demarest, Brian Robert Miller, William B. Snyder, Xiufeng Wu, Norman Wang, Lisa J. Croner, Alexey Alexandrovich Lugovskoy
Abstract: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.
Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.
Type:
Application
Filed:
March 26, 2014
Publication date:
October 30, 2014
Applicant:
Biogen Idec MA Inc.
Inventors:
Anthony Rossomando, R. Blake Pepinsky, BangJian Gong